Danbury, CT, United States of America

Cheng-Kon Shih

USPTO Granted Patents = 2 



Average Co-Inventor Count = 12.0

ph-index = 1

Forward Citations = 38(Granted Patents)


Company Filing History:


Years Active: 2014-2020

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):

Title: The Innovative Contributions of Inventor Cheng-Kon Shih

Introduction:

Cheng-Kon Shih is a notable inventor based in Danbury, Connecticut, who has made significant strides in the field of pharmaceutical research. With an impressive portfolio of two patents, his work focuses on developing innovative compounds that serve as Rho kinase inhibitors, contributing to advancements in treating various diseases.

Latest Patents:

Cheng-Kon Shih's latest patents revolve around novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives. These compounds are designed to be effective inhibitors of Rho kinase, a critical enzyme involved in several pathophysiological processes. His patents detail methods for utilizing these compounds and processes for their synthesis, addressing cardiovascular diseases and other disorders sustained through the activity of Rho kinase. These innovations not only showcase his creativity but also hold promise for significant medical advancements.

Career Highlights:

Cheng-Kon Shih is affiliated with Aerie Pharmaceuticals, Inc., where he contributes his expertise to further the company's mission of developing innovative therapies. His focus on Rho kinase inhibitors reflects the company's commitment to addressing unmet medical needs through research and development.

Collaborations:

Throughout his career, Cheng-Kon Shih has worked alongside esteemed colleagues, including Todd Bosanac and John David Ginn. These collaborations foster an environment of shared knowledge and innovation, enabling the team to push the boundaries of pharmaceutical science together.

Conclusion:

Inventor Cheng-Kon Shih stands as a testament to the power of innovation in the pharmaceutical industry. By developing groundbreaking Rho kinase inhibitors, he showcases his dedication to improving health outcomes for patients. His work continues to influence the field, and his collaborative spirit is evident in his partnerships with fellow researchers.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…